Leerink Partners analyst Andrew Berens reiterated a Buy rating on Kinnate Biopharma on Thursday, setting a price target of $52, which is approximately 126.19% above the present share price of $22.99.
Berens expects Kinnate Biopharma to post earnings per share (EPS) of -$0.49 for the fourth quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Kinnate Biopharma, with an average price target of $47.
The analysts price targets range from a high of $53 to a low of $32.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $0 and a net profit of -$21.57 million. The company's market cap is $1 billion.
According to TipRanks.com, Leerink Partners analyst Andrew Berens is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 5.2% and a 58.85% success rate.
Kinnate Biopharma Inc a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. The company's product candidate is KIN002787, which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor it is developing for the treatment of patients with lung cancer, melanoma and other solid tumors. Its KIN003 program is evaluating Fibroblast Growth Factor Receptors (FGFR) inhibitor candidates for the treatment of patients with intrahepatic cholangiocarcinoma (ICC), a cancer of the bile ducts in the liver, and urothelial carcinoma (UC), a cancer of the bladder lining.